<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02996630</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AMI)317/2012</org_study_id>
    <nct_id>NCT02996630</nct_id>
  </id_info>
  <brief_title>Assessing Neurodevelopment in Congenital Heart Disease.</brief_title>
  <acronym>NEUROHEART</acronym>
  <official_title>Abnormal Neurodevelopment Detection in Congenital Heart Disease: Predictive Methods Based on Prenatal and Postnatal Factors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Mara√±on</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital heart disease (CHD) is the most prevalent congenital malformation affecting 1 in
      100 newborns per year. Children with CHD are a known risk population for brain injury, with
      neurodevelopmental alterations shown over time in up to 50% of cases. No adequate description
      exists of the type of neurocognitive anomalies or risk factors associated with CHD, and
      consequently no prognostic markers that may allow identification of high-risk cases are
      available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of this study are: 1. to describe the neurodevelopmental outcome of
      patients with CHD at 24 months of age; 2. identify the subgroup with poorer outcome; and 3.
      evaluate the utility of fetal and postnatal diagnostic techniques for early detection of
      patients at risk for altered neurological outcomes.

      Seven Spanish referral centers for CHD included in the research network on maternal and child
      health currently participating in this prospective multicentric case-control coordinated
      study. Fetuses with CHD (transposition of great arteries, tetralogy of Fallot, hypoplastic
      left heart syndrome and septal defects) will be studied from 24 weeks of gestation to 2 years
      of age. Diagnostic tests will be repeated throughout the study in all patients, from the
      fetal period to 24 months of age, and will include: fetal cerebral hemodynamic Doppler
      assessment, functional echocardiography, brain MRI, regional cerebral oxymetry,
      electroencephalography and serum neurological and cardiac biomarkers analysis.
      Neurodevelopmental assessment will be made at 12 months of age using the ages and stages
      questionnaire (ASQ) and at 24 months of age with the Bayley-III test. From this data,
      statistical analysis will select the most useful as predictors of damage; to be then combined
      and create algorithms for predicting brain damage and poor neurodevelopment. Once description
      has been made, we will proceed to identify amongst our results, children with the poorest
      neurological outcome and remark possible common prenatal and early life markers in them as
      well as the CHD severity they present.

      While advances in early diagnosis and postnatal management have increased survival in CHD
      children, worrying long-term outcomes, particularly neurodevelopmental disability, have
      emerged as a key prognostic factor in the counseling of these pregnancies. Evidence available
      does not allow clinicians to assess on neurological prognosis although has opened up the
      possibility of finding prenatal markers of brain damage. Even though, no prospective studies
      have been performed until now. We present a multicentric prospective study able to recruit
      enough fetal CHD affected pregnancies to obtain neurological prognostic tools.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bailey-III test punctuation</measure>
    <time_frame>45 minutes</time_frame>
    <description>Results in pediatric Bailey-III test scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biparietal diameter (mm)</measure>
    <time_frame>one day</time_frame>
    <description>Biparietal diameter (mm) measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lateral sulcus depth</measure>
    <time_frame>one day</time_frame>
    <description>Lateral sulcus depth (mm) measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral insula</measure>
    <time_frame>one day</time_frame>
    <description>Insula (mm) measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain biometries</measure>
    <time_frame>one day</time_frame>
    <description>Calcarine sulcus depth (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral cingulata sulcus</measure>
    <time_frame>one day</time_frame>
    <description>Cingulata sulcus depth (mm) measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corpus callosum</measure>
    <time_frame>one day</time_frame>
    <description>Corpus callosum (mm) measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebellum</measure>
    <time_frame>one day</time_frame>
    <description>Cerebellum vermis (mm) measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical doppler</measure>
    <time_frame>one day</time_frame>
    <description>Umbilical artery pulsatility index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Middle cerebral artery doppler</measure>
    <time_frame>one day</time_frame>
    <description>Middle cerebral artery pulsatility index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic PLGF (placental growth factor)</measure>
    <time_frame>Two days</time_frame>
    <description>Placental growth factor in maternal serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic s-FLt (soluble fms-like tyrosine kinase)</measure>
    <time_frame>Two days</time_frame>
    <description>Soluble fms-like tyrosine kinase factor in maternal serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Healthy fetuses</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Congenital Hearth Disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sonography</intervention_name>
    <description>Fetal Ultrasound exploration</description>
    <arm_group_label>Healthy fetuses</arm_group_label>
    <arm_group_label>Congenital Hearth Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Fetal MRI for brain study</description>
    <arm_group_label>Healthy fetuses</arm_group_label>
    <arm_group_label>Congenital Hearth Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bailey Test</intervention_name>
    <description>Neurodevelopment paediatric assessment test performed at 2 years of age.</description>
    <arm_group_label>Healthy fetuses</arm_group_label>
    <arm_group_label>Congenital Hearth Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical intervention</intervention_name>
    <description>Congenital Heart Disease repair</description>
    <arm_group_label>Congenital Hearth Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain monitoring</intervention_name>
    <description>EEG and continuous brain oximetry before surgery.</description>
    <arm_group_label>Congenital Hearth Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cord blood sample</intervention_name>
    <description>Cord blood samples will be taken after birth in both groups.</description>
    <arm_group_label>Healthy fetuses</arm_group_label>
    <arm_group_label>Congenital Hearth Disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Single pregnancies

          -  Major Congenital Heart Disease

          -  Informed Consent Signed

        Exclusion Criteria:

          -  Major extra-cardiac malformations

          -  Parental Refusal to participate

          -  Maternal Chronic Disease

          -  Multiple Pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa Llurba, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitari Vall d'Hebr√≥n</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Ribera, MD</last_name>
    <phone>934893000</phone>
    <phone_ext>3086</phone_ext>
    <email>irene.ribera@vhir.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aina Ruiz, MD</last_name>
    <phone>934893000</phone>
    <phone_ext>3086</phone_ext>
    <email>aruizrom@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebr√≥n</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Ribera, Dr</last_name>
      <phone>934893000</phone>
      <phone_ext>3086</phone_ext>
      <email>irene.ribera@vhir.org</email>
    </contact>
    <contact_backup>
      <last_name>Elisa Llurba, Dr</last_name>
      <phone>934893000</phone>
      <phone_ext>3086</phone_ext>
      <email>irene.ribera@vhir.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002 Jun 19;39(12):1890-900. Review.</citation>
    <PMID>12084585</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellinger DC, Jonas RA, Rappaport LA, Wypij D, Wernovsky G, Kuban KC, Barnes PD, Holmes GL, Hickey PR, Strand RD, et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. N Engl J Med. 1995 Mar 2;332(9):549-55.</citation>
    <PMID>7838188</PMID>
  </results_reference>
  <results_reference>
    <citation>Limperopoulos C, Majnemer A, Shevell MI, Rosenblatt B, Rohlicek C, Tchervenkov C. Neurodevelopmental status of newborns and infants with congenital heart defects before and after open heart surgery. J Pediatr. 2000 Nov;137(5):638-45.</citation>
    <PMID>11060529</PMID>
  </results_reference>
  <results_reference>
    <citation>Masoller N, Mart√≠nez JM, G√≥mez O, Bennasar M, Crispi F, Sanz-Cort√©s M, Ega√±a-Ugrinovic G, Bartrons J, Puerto B, Gratac√≥s E. Evidence of second-trimester changes in head biometry and brain perfusion in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2014 Aug;44(2):182-7. doi: 10.1002/uog.13373. Epub 2014 Jul 8.</citation>
    <PMID>24687311</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruiz A, Cruz-Lemini M, Masoller N, Sanz-Cort√©s M, Ferrer Q, Ribera I, Mart√≠nez JM, Crispi F, Ar√©valo S, G√≥mez O, P√©rez-Hoyos S, Carreras E, Gratac√≥s E, Llurba E. Longitudinal changes in fetal biometry and cerebroplacental hemodynamics in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2017 Mar;49(3):379-386. doi: 10.1002/uog.15970.</citation>
    <PMID>27214694</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2016</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LVOTO</keyword>
  <keyword>Fallot</keyword>
  <keyword>Great Arteries Transposition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

